Akademik Veri Yönetim Sistemi
Turkiye Klinikleri Jinekoloji Obstetrik, cilt.20, sa.6, ss.387-391, 2010 (Scopus)
Imatinib that first administered to patients with chronic myeloid leukemia (CML) in June 1998 is a potent inhibitor of tyrosine kinase used in the treatment of with positive Philadelphia chromosome CML, acute lymphoblastic leukemia and gastrointestinal stromal tumors (GISTs). In recent years pregnant women exposed to imatinib are observed more frequently, because of increasing the survival of the patients diagnosed with CML and GISTs during the reproductive age. Owing to its teratogenic effects demonstrated in the animal trials, imatinib is not recommended in pregnant or during the reproductive age, and an effective contraception is recommended to the reproductive women undergoing to the treatment. Due to use imatinib during pregnancy, few abortuses and various congenital anomalies are noted along with successful singleton and multiple pregnancies. The pregnancy of a patient with a chronic myeloid leukemia requiring treatment presents a dilemma, both to the physician and to the patient. Therefore, the potential risks must be considered carefully, when deciding imatinib therapy for pregnant and lactating women. In this paper, we reported two cases who were exposed to imatinib in first trimester of their pregnanc and gave a birth with inguinal hernia and the other gave a healthy baby. We also discussed the safety and the effects of imatinib during pregnancy and lactation period for mother and fetus. Copyright © 2010 by Türkiye Klinikleri.